Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
Inventors
GREENFIELD, SUSAN ADELE • PEPPER, Christopher
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11033609-B2
Publication Date
2021-06-15
Expiration Date
Abstract
The invention relates to cyclic polypeptides derived from the C-terminus of acetylcholinesterase for use in treating or preventing cancer or metastatic disease.
Core Innovation
The patent describes cyclic acetylcholinesterase C-terminus-derived peptides, including cyclic SEQ ID No:3 (also identified as NBP-14/CT14/cyclated T14), for treating or preventing cancer and metastasis. It frames the invention around cyclic polypeptides defined by sequence identity to SEQ ID No:3 and associated derivations, truncations, and cyclization approaches.
The patent addresses the need for methods and compositions for treating or ameliorating cancer and metastasis. The disclosed rationale and in vitro results support anti-cancer activity, including apoptosis and anti-proliferative effects across multiple cancer cell lines and primary CLL cells, along with reported non-toxicity in normal B- and T-lymphocytes.
The patent further describes anti-migratory effects, exemplified by dose-dependent activity reported in transwell migration assays in several cancer models for NBP-14, without significant cytotoxicity driving the observed effect. It also identifies specific target cancer indications including breast cancer, CLL/lymphocytic leukemia, acute myeloid leukemia, myeloid leukemia, and multiple myeloma.
Claims Coverage
The document provides one independent claim directed to a method of treating or ameliorating cancer by administering a cyclic polypeptide meeting a sequence identity threshold, with the cancer indication limited to enumerated types. A dependent claim further narrows the indication to breast cancer.
Treating or ameliorating enumerated cancers with a cyclic polypeptide matching SEQ ID No:3
Administering a therapeutically effective amount of a cyclic polypeptide having at least 85% sequence identity with SEQ ID No: 3 to a subject in need of such treatment, wherein the cancer is breast cancer, lymphocytic leukemia, chronic lymphocytic leukemia (CLL), myeloid leukemia or acute myeloid leukemia.
Breast cancer indication narrowing
Using the method for treating or ameliorating breast cancer.
Overall, claim coverage centers on administering a therapeutically effective amount of a cyclic polypeptide defined by at least 85% sequence identity to SEQ ID No: 3, with enumerated cancer indications, and includes an additional narrowing dependent feature specific to breast cancer.
Stated Advantages
Reported modest apoptosis and anti-proliferative activity across multiple cancer cell lines and primary CLL samples.
Reported non-toxicity in normal B-lymphocytes and normal T-lymphocytes.
Reported dose-dependent anti-migratory (anti-metastatic) effects in transwell migration assays.
Documented Applications
Treating or preventing cancer and metastasis, including breast cancer, CLL/lymphocytic leukemia, acute myeloid leukemia, myeloid leukemia, and multiple myeloma.
Using cyclic SEQ ID No:3-based peptides (e.g., NBP-14/CT14/cyclated T14) to evaluate in vitro anti-cancer activity and anti-migratory activity, including transwell migration assays.
Interested in licensing this patent?